ID   TPMT_HUMAN              Reviewed;         245 AA.
AC   P51580; O14806; O15423; O15424; O15425; O15426; O15515; O15548;
AC   O43213; Q5VUK6; Q9UBE6; Q9UBT8; Q9UE62;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 175.
DE   RecName: Full=Thiopurine S-methyltransferase;
DE            EC=2.1.1.67;
DE   AltName: Full=Thiopurine methyltransferase;
GN   Name=TPMT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Kidney;
RX   PubMed=8316220;
RA   Honchel R., Aksoy I.A., Szumlanski C., Wood T.C., Otterness D.M.,
RA   Wieben E.D., Weinshilboum R.M.;
RT   "Human thiopurine methyltransferase: molecular cloning and expression
RT   of T84 colon carcinoma cell cDNA.";
RL   Mol. Pharmacol. 43:878-887(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7628307;
RA   Lee D., Szumlanski C.L., Houtman J., Honchel R., Rojas K.,
RA   Overhauser J., Weiben E.D., Weinshilboum R.M.;
RT   "Thiopurine methyltransferase pharmacogenetics. Cloning of human liver
RT   cDNA and a processed pseudogene on human chromosome 18q21.1.";
RL   Drug Metab. Dispos. 23:398-405(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-154 AND CYS-240.
RX   PubMed=8561894; DOI=10.1089/dna.1996.15.17;
RA   Szumlanski C., Otterness D., Her C., Lee D., Brandriff B., Kelsell D.,
RA   Spurr N., Lennard L., Wieben E., Weinshilboum R.M.;
RT   "Thiopurine methyltransferase pharmacogenetics: human gene cloning and
RT   characterization of a common polymorphism.";
RL   DNA Cell Biol. 15:17-30(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9453052; DOI=10.1023/A:1012111325397;
RA   Krynetski E.Y., Fessing M.Y., Yates C.R., Sun D., Schuetz J.D.,
RA   Evans W.E.;
RT   "Promoter and intronic sequences of the human thiopurine S-
RT   methyltransferase (TPMT) gene isolated from a human PAC1 genomic
RT   library.";
RL   Pharm. Res. 14:1672-1678(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-49; THR-154;
RP   PHE-180 AND CYS-240.
RX   PubMed=9246020; DOI=10.1016/S0009-9236(97)90152-1;
RA   Otterness D., Szumlanski C., Lennard L., Klemetsdal B., Aarbakke J.,
RA   Park-Hah J.O., Iven H., Schmiegelow K., Branum E., O'Brien J.,
RA   Weinshilboum R.M.;
RT   "Human thiopurine methyltransferase pharmacogenetics: gene sequence
RT   polymorphisms.";
RL   Clin. Pharmacol. Ther. 62:60-73(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Nakamura Y.;
RT   "Genomic structure of thiopurine S-methyltransferase gene.";
RL   Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Bone marrow;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 210-245, AND VARIANT GLN-227.
RX   PubMed=9711875;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:3<177::AID-HUMU5>3.0.CO;2-E;
RA   Spire-Vayron de la Moureyre C., Debuysere H., Sabbagh N., Marez D.,
RA   Vinner E., Chevalier E.D., Lo-Guidice J.-M., Broly F.;
RT   "Detection of known and new mutations in the thiopurine S-
RT   methyltransferase gene by single-strand conformation polymorphism
RT   analysis.";
RL   Hum. Mutat. 12:177-185(1998).
RN   [10]
RP   CATALYTIC ACTIVITY, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   MUTAGENESIS OF ARG-152.
RX   PubMed=18484748; DOI=10.1021/bi800102x;
RA   Peng Y., Feng Q., Wilk D., Adjei A.A., Salavaggione O.E.,
RA   Weinshilboum R.M., Yee V.C.;
RT   "Structural basis of substrate recognition in thiopurine s-
RT   methyltransferase.";
RL   Biochemistry 47:6216-6225(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-58, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.58 ANGSTROMS) OF 16-245 IN COMPLEX WITH
RP   S-ADENOSYL-L-HOMOCYSTEINE, SUBUNIT, AND CHARACTERIZATION OF VARIANTS
RP   THR-154 AND CYS-240.
RX   PubMed=17243178; DOI=10.1002/prot.21272;
RA   Wu H., Horton J.R., Battaile K., Allali-Hassani A., Martin F.,
RA   Zeng H., Loppnau P., Vedadi M., Bochkarev A., Plotnikov A.N.,
RA   Cheng X.;
RT   "Structural basis of allele variation of human thiopurine-S-
RT   methyltransferase.";
RL   Proteins 67:198-208(2007).
RN   [19]
RP   VARIANT PRO-80.
RX   PubMed=7862671; DOI=10.1073/pnas.92.4.949;
RA   Krynetski E.Y., Schuetz J.D., Galpin A.J., Pui C.-H., Relling M.V.,
RA   Evans W.E.;
RT   "A single point mutation leading to loss of catalytic activity in
RT   human thiopurine S-methyltransferase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:949-953(1995).
RN   [20]
RP   VARIANTS THR-154 AND CYS-240.
RX   PubMed=8644731;
RA   Tai H.-L., Krynetski E.Y., Yates C.R., Loennechen T., Fessing M.Y.,
RA   Krynetskaia N.F., Evans W.E.;
RT   "Thiopurine S-methyltransferase deficiency: two nucleotide transitions
RT   define the most prevalent mutant allele associated with loss of
RT   catalytic activity in Caucasians.";
RL   Am. J. Hum. Genet. 58:694-702(1996).
RN   [21]
RP   VARIANTS THR-154 AND CYS-240.
RX   PubMed=9336428; DOI=10.1002/art.1780401026;
RA   Leipold G., Schuetz E., Haas J.P., Oellerich M.;
RT   "Azathioprine-induced severe pancytopenia due to a homozygous two-
RT   point mutation of the thiopurine methyltransferase gene in a patient
RT   with juvenile HLA-B27-associated spondylarthritis.";
RL   Arthritis Rheum. 40:1896-1898(1997).
RN   [22]
RP   CHARACTERIZATION OF VARIANTS PRO-80 AND THR-154, AND MECHANISM FOR THE
RP   GENETIC POLYMORPHISM OF TPMT ACTIVITY.
RX   PubMed=9177237; DOI=10.1073/pnas.94.12.6444;
RA   Tai H.-L., Krynetski E.Y., Schuetz E.G., Yanishevski Y., Evans W.E.;
RT   "Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded
RT   by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the
RT   genetic polymorphism of TPMT activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:6444-6449(1997).
RN   [23]
RP   VARIANTS PRO-80; THR-154 AND CYS-240.
RX   PubMed=9931345; DOI=10.1093/hmg/8.2.367;
RA   Ameyaw M.-M., Collie-Duguid E.S.R., Powrie R.H., Ofori-Adjei D.,
RA   McLeod H.L.;
RT   "Thiopurine methyltransferase alleles in British and Ghanaian
RT   populations.";
RL   Hum. Mol. Genet. 8:367-370(1999).
RN   [24]
RP   VARIANT HIS-215.
RX   PubMed=9931346; DOI=10.1093/hmg/8.2.371;
RA   Hon Y.Y., Fessing M.Y., Pui C.-H., Relling M.V., Krynetski E.Y.,
RA   Evans W.E.;
RT   "Polymorphism of the thiopurine S-methyltransferase gene in African-
RT   Americans.";
RL   Hum. Mol. Genet. 8:371-376(1999).
RN   [25]
RP   VARIANTS PRO-80; THR-154 AND CYS-240, AND FREQUENCY AND DISTRIBUTION
RP   OF ALLELES.
RX   PubMed=10208641;
RA   Collie-Duguid E.S.R., Pritchard S.C., Powrie R.H., Sludden J.,
RA   Collier D.A., Li T., McLeod H.L.;
RT   "The frequency and distribution of thiopurine methyltransferase
RT   alleles in Caucasian and Asian populations.";
RL   Pharmacogenetics 9:37-42(1999).
RN   [26]
RP   VARIANTS PRO-80; THR-154 AND CYS-240, AND FREQUENCY AND DISTRIBUTION
RP   OF ALLELES.
RX   PubMed=10751626; DOI=10.1016/S0027-5107(00)00004-X;
RA   Hiratsuka M., Inoue T., Omori F., Agatsuma Y., Mizugaki M.;
RT   "Genetic analysis of thiopurine methyltransferase polymorphism in a
RT   Japanese population.";
RL   Mutat. Res. 448:91-95(2000).
RN   [27]
RP   VARIANTS SER-49; PRO-80; THR-154; PHE-180; HIS-215; GLN-227 AND
RP   CYS-240, AND CHARACTERIZATION OF VARIANTS SER-49; PRO-80; THR-154;
RP   PHE-180; HIS-215; GLN-227 AND CYS-240.
RX   PubMed=16220112; DOI=10.1097/01.fpc.0000174788.69991.6b;
RA   Salavaggione O.E., Wang L., Wiepert M., Yee V.C., Weinshilboum R.M.;
RT   "Thiopurine S-methyltransferase pharmacogenetics: variant allele
RT   functional and comparative genomics.";
RL   Pharmacogenet. Genomics 15:801-815(2005).
RN   [28]
RP   VARIANTS THR-154 AND CYS-240.
RX   PubMed=15819814; DOI=10.1111/j.1432-2277.2005.00095.x;
RA   Kurzawski M., Dziewanowski K., Ciechanowski K., Drozdzik M.;
RT   "Severe azathioprine-induced myelotoxicity in a kidney transplant
RT   patient with thiopurine S-methyltransferase-deficient genotype
RT   (TPMT*3A/*3C).";
RL   Transpl. Int. 18:623-625(2005).
RN   [29]
RP   VARIANTS PRO-80; THR-154 AND CYS-240, AND FREQUENCY AND DISTRIBUTION
RP   OF ALLELES.
RX   PubMed=16476125; DOI=10.1111/j.1365-2710.2006.00707.x;
RA   Lu H.-F., Shih M.-C., Chang Y.-S., Chang J.-Y., Ko Y.-C., Chang S.-J.,
RA   Chang J.-G.;
RT   "Molecular analysis of thiopurine S-methyltransferase alleles in
RT   Taiwan aborigines and Taiwanese.";
RL   J. Clin. Pharm. Ther. 31:93-98(2006).
RN   [30]
RP   VARIANTS PRO-80; THR-154 AND CYS-240, AND FREQUENCY AND DISTRIBUTION
RP   OF ALLELES.
RX   PubMed=16789994; DOI=10.1111/j.1365-2710.2006.00736.x;
RA   Rossino R., Vincis C., Alves S., Prata M.J., Macis M.D., Nucaro A.L.,
RA   Schirru E., Congia M.;
RT   "Frequency of the thiopurine S-methyltransferase alleles in the
RT   ancient genetic population isolate of Sardinia.";
RL   J. Clin. Pharm. Ther. 31:283-287(2006).
CC   -!- FUNCTION: Catalyzes the S-methylation of thiopurine drugs such as
CC       6-mercaptopurine. {ECO:0000269|PubMed:18484748}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + a thiopurine = S-
CC       adenosyl-L-homocysteine + a thiopurine S-methylether.
CC       {ECO:0000269|PubMed:18484748}.
CC   -!- ENZYME REGULATION: Inhibited by S-adenosyl-L-homocysteine (SAH).
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=5.6 mM for S-adenosyl-L-methionine
CC         {ECO:0000269|PubMed:18484748};
CC         KM=0.35 mM for 6-mercaptopurine {ECO:0000269|PubMed:18484748};
CC         Vmax=0.6 nmol/sec/mg enzyme toward 6-mercaptopurine (at 37
CC         degrees Celsius) {ECO:0000269|PubMed:18484748};
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:17243178}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- POLYMORPHISM: Polymorphic variations define TPMT activity levels
CC       that are variable among ethnic groups. 90% of Caucasians have high
CC       TPMT activity, 10% have intermediate activity, and 1 in 300
CC       individuals has low activity (PubMed:10208641). These differences
CC       influence the clinical use and therapeutic efficacy of thiopurine
CC       drugs, generally used as immunosuppressants or cytotoxic drugs in
CC       conditions including leukemia, autoimmune disease and organ
CC       transplantation. Intermediate or low TPMT activity is associated
CC       with thiopurine intolerance and patients are at risk of toxicity
CC       after receiving standard doses of thiopurine drugs [MIM:610460]
CC       (PubMed:10751626, PubMed:15819814, PubMed:16220112,
CC       PubMed:16476125, PubMed:16789994, PubMed:7862671, PubMed:8561894,
CC       PubMed:8644731, PubMed:9246020, PubMed:9336428, PubMed:9711875,
CC       PubMed:9931345, PubMed:9931346). The most prevalent TPMT alleles
CC       associated with TPMT deficiency are TPMT*2 and TPMT*3A. The
CC       proteins encoded by TPMT*2 and TPMT*3A mutant are degraded more
CC       rapidly by an ATP-dependent proteasome-mediated pathway
CC       (PubMed:9177237, PubMed:8644731). {ECO:0000269|PubMed:10208641,
CC       ECO:0000269|PubMed:10751626, ECO:0000269|PubMed:15819814,
CC       ECO:0000269|PubMed:16220112, ECO:0000269|PubMed:16476125,
CC       ECO:0000269|PubMed:16789994, ECO:0000269|PubMed:7862671,
CC       ECO:0000269|PubMed:8561894, ECO:0000269|PubMed:8644731,
CC       ECO:0000269|PubMed:9177237, ECO:0000269|PubMed:9246020,
CC       ECO:0000269|PubMed:9336428, ECO:0000269|PubMed:9711875,
CC       ECO:0000269|PubMed:9931345, ECO:0000269|PubMed:9931346}.
CC   -!- POLYMORPHISM: TPMT*3A is the most common allele in the Caucasians
CC       and American Caucasians; it is the only mutant allele found in the
CC       South West Asians; it is not found in the Chinese. TPMT*3C is
CC       common in African-Americans and is the only allele in Chinese,
CC       Japanese and Taiwanese individuals. This allele is found at a low
CC       frequency in the Caucasians. This suggests that TPMT*3C is the
CC       oldest mutation, with TPMT*3B being acquired later to form the
CC       TPMT*3A allele in the Caucasian and South West Asian populations.
CC       TPMT*2 appears to be a more recent allele, which has only been
CC       detected in Caucasians to date. {ECO:0000269|PubMed:10208641,
CC       ECO:0000269|PubMed:10751626, ECO:0000269|PubMed:16476125}.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding
CC       methyltransferase superfamily. TPMT family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB71631.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAB71632.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S62904; AAB27277.1; -; mRNA.
DR   EMBL; U12387; AAC50130.1; -; mRNA.
DR   EMBL; U30518; AAC50368.1; -; Genomic_DNA.
DR   EMBL; U30512; AAC50368.1; JOINED; Genomic_DNA.
DR   EMBL; U30513; AAC50368.1; JOINED; Genomic_DNA.
DR   EMBL; U30514; AAC50368.1; JOINED; Genomic_DNA.
DR   EMBL; U30515; AAC50368.1; JOINED; Genomic_DNA.
DR   EMBL; U30516; AAC50368.1; JOINED; Genomic_DNA.
DR   EMBL; U30517; AAC50368.1; JOINED; Genomic_DNA.
DR   EMBL; AF019369; AAC51865.1; -; Genomic_DNA.
DR   EMBL; AF019364; AAC51865.1; JOINED; Genomic_DNA.
DR   EMBL; AF019365; AAC51865.1; JOINED; Genomic_DNA.
DR   EMBL; AF019366; AAC51865.1; JOINED; Genomic_DNA.
DR   EMBL; AF019367; AAC51865.1; JOINED; Genomic_DNA.
DR   EMBL; AF019368; AAC51865.1; JOINED; Genomic_DNA.
DR   EMBL; U81562; AAB71625.1; -; Genomic_DNA.
DR   EMBL; U81563; AAB71626.1; -; Genomic_DNA.
DR   EMBL; U81564; AAB71627.1; -; Genomic_DNA.
DR   EMBL; U81565; AAB71628.1; -; Genomic_DNA.
DR   EMBL; U81566; AAB71629.1; -; Genomic_DNA.
DR   EMBL; U81567; AAB71630.1; -; Genomic_DNA.
DR   EMBL; U81568; AAB71631.1; ALT_INIT; Genomic_DNA.
DR   EMBL; U81569; AAB71632.1; ALT_INIT; Genomic_DNA.
DR   EMBL; U81570; AAB71633.1; -; Genomic_DNA.
DR   EMBL; U81571; AAB71634.1; -; Genomic_DNA.
DR   EMBL; U81572; AAB71635.1; -; Genomic_DNA.
DR   EMBL; U81573; AAB71636.1; -; Genomic_DNA.
DR   EMBL; AB045146; BAA97037.1; -; Genomic_DNA.
DR   EMBL; AL589723; CAH71233.1; -; Genomic_DNA.
DR   EMBL; BC009596; AAH09596.1; -; mRNA.
DR   EMBL; AF035426; AAC32289.1; -; Genomic_DNA.
DR   EMBL; AF021876; AAB80746.1; -; mRNA.
DR   EMBL; AF021877; AAB80747.1; -; mRNA.
DR   CCDS; CCDS4543.1; -.
DR   PIR; I57946; I57946.
DR   RefSeq; NP_000358.1; NM_000367.4.
DR   RefSeq; NP_001333746.1; NM_001346817.1.
DR   RefSeq; NP_001333747.1; NM_001346818.1.
DR   UniGene; Hs.444319; -.
DR   PDB; 2BZG; X-ray; 1.58 A; A=16-245.
DR   PDB; 2H11; X-ray; 1.89 A; A/B=17-245.
DR   PDBsum; 2BZG; -.
DR   PDBsum; 2H11; -.
DR   ProteinModelPortal; P51580; -.
DR   SMR; P51580; -.
DR   BioGrid; 113025; 1.
DR   STRING; 9606.ENSP00000312304; -.
DR   BindingDB; P51580; -.
DR   ChEMBL; CHEMBL2500; -.
DR   DrugBank; DB00993; Azathioprine.
DR   DrugBank; DB00436; Bendroflumethiazide.
DR   DrugBank; DB01327; Cefazolin.
DR   DrugBank; DB01033; Mercaptopurine.
DR   DrugBank; DB01250; Olsalazine.
DR   DrugBank; DB01021; Trichlormethiazide.
DR   iPTMnet; P51580; -.
DR   PhosphoSitePlus; P51580; -.
DR   BioMuta; TPMT; -.
DR   DMDM; 1730006; -.
DR   EPD; P51580; -.
DR   MaxQB; P51580; -.
DR   PaxDb; P51580; -.
DR   PeptideAtlas; P51580; -.
DR   PRIDE; P51580; -.
DR   DNASU; 7172; -.
DR   Ensembl; ENST00000309983; ENSP00000312304; ENSG00000137364.
DR   GeneID; 7172; -.
DR   KEGG; hsa:7172; -.
DR   UCSC; uc003ncm.4; human.
DR   CTD; 7172; -.
DR   DisGeNET; 7172; -.
DR   GeneCards; TPMT; -.
DR   HGNC; HGNC:12014; TPMT.
DR   HPA; HPA019851; -.
DR   MalaCards; TPMT; -.
DR   MIM; 187680; gene.
DR   MIM; 610460; phenotype.
DR   neXtProt; NX_P51580; -.
DR   OpenTargets; ENSG00000137364; -.
DR   Orphanet; 413687; Azathioprine or 6-mercatopurine toxicity or dose selection.
DR   Orphanet; 240863; Cisplatin toxicity.
DR   Orphanet; 3315; Thiopurine S-methyltransferase deficiency.
DR   PharmGKB; PA356; -.
DR   eggNOG; ENOG410IGTR; Eukaryota.
DR   eggNOG; ENOG4111GNF; LUCA.
DR   GeneTree; ENSGT00390000016823; -.
DR   HOVERGEN; HBG003037; -.
DR   InParanoid; P51580; -.
DR   KO; K00569; -.
DR   OMA; KWVNGKT; -.
DR   OrthoDB; EOG091G0VS2; -.
DR   PhylomeDB; P51580; -.
DR   TreeFam; TF328951; -.
DR   BRENDA; 2.1.1.67; 2681.
DR   Reactome; R-HSA-156581; Methylation.
DR   ChiTaRS; TPMT; human.
DR   EvolutionaryTrace; P51580; -.
DR   GeneWiki; Thiopurine_methyltransferase; -.
DR   GenomeRNAi; 7172; -.
DR   PRO; PR:P51580; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000137364; -.
DR   ExpressionAtlas; P51580; baseline and differential.
DR   Genevisible; P51580; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0008119; F:thiopurine S-methyltransferase activity; TAS:Reactome.
DR   GO; GO:0032259; P:methylation; TAS:Reactome.
DR   GO; GO:0006139; P:nucleobase-containing compound metabolic process; TAS:ProtInc.
DR   HAMAP; MF_00812; Thiopur_methtran; 1.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   InterPro; IPR025835; Thiopurine_S-MeTrfase.
DR   InterPro; IPR008854; TPMT.
DR   PANTHER; PTHR10259; PTHR10259; 1.
DR   Pfam; PF05724; TPMT; 1.
DR   PIRSF; PIRSF023956; Thiopurine_S-methyltransferase; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   PROSITE; PS51585; SAM_MT_TPMT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Methyltransferase; Phosphoprotein;
KW   Polymorphism; Reference proteome; S-adenosyl-L-methionine;
KW   Transferase.
FT   CHAIN         1    245       Thiopurine S-methyltransferase.
FT                                /FTId=PRO_0000220102.
FT   REGION       29     40       S-adenosyl-L-methionine binding.
FT   REGION      134    135       S-adenosyl-L-methionine binding.
FT   BINDING      40     40       Substrate. {ECO:0000250}.
FT   BINDING      69     69       S-adenosyl-L-methionine; via carbonyl
FT                                oxygen.
FT   BINDING      90     90       S-adenosyl-L-methionine.
FT   BINDING     152    152       S-adenosyl-L-methionine.
FT   MOD_RES      14     14       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES      58     58       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VARIANT      49     49       L -> S (polymorphism; allele TPMT*5; has
FT                                very low activity when expressed in a
FT                                heterologous system; dbSNP:rs72552740).
FT                                {ECO:0000269|PubMed:16220112,
FT                                ECO:0000269|PubMed:9246020}.
FT                                /FTId=VAR_005636.
FT   VARIANT      80     80       A -> P (polymorphism; allele TPMT*2;
FT                                TPMT*2 allele frequency is 0.5%; seems to
FT                                be restricted to the Caucasian
FT                                population; 100-fold reduction in
FT                                activity; protein shows enhanced
FT                                degradation; dbSNP:rs1800462).
FT                                {ECO:0000269|PubMed:10208641,
FT                                ECO:0000269|PubMed:10751626,
FT                                ECO:0000269|PubMed:16220112,
FT                                ECO:0000269|PubMed:16476125,
FT                                ECO:0000269|PubMed:16789994,
FT                                ECO:0000269|PubMed:7862671,
FT                                ECO:0000269|PubMed:9177237,
FT                                ECO:0000269|PubMed:9931345}.
FT                                /FTId=VAR_005637.
FT   VARIANT     154    154       A -> T (polymorphism; allele TPMT*3A and
FT                                allele TPMT*3B; very low activity;
FT                                protein shows enhanced degradation
FT                                leading to strongly reduced protein
FT                                levels; dbSNP:rs1800460).
FT                                {ECO:0000269|PubMed:10208641,
FT                                ECO:0000269|PubMed:10751626,
FT                                ECO:0000269|PubMed:15819814,
FT                                ECO:0000269|PubMed:16220112,
FT                                ECO:0000269|PubMed:16476125,
FT                                ECO:0000269|PubMed:16789994,
FT                                ECO:0000269|PubMed:17243178,
FT                                ECO:0000269|PubMed:8561894,
FT                                ECO:0000269|PubMed:8644731,
FT                                ECO:0000269|PubMed:9177237,
FT                                ECO:0000269|PubMed:9246020,
FT                                ECO:0000269|PubMed:9336428,
FT                                ECO:0000269|PubMed:9931345}.
FT                                /FTId=VAR_005638.
FT   VARIANT     179    179       Q -> H (in dbSNP:rs6921269).
FT                                /FTId=VAR_052368.
FT   VARIANT     180    180       Y -> F (polymorphism; allele TPMT*6;
FT                                reduced activity; dbSNP:rs75543815).
FT                                {ECO:0000269|PubMed:16220112,
FT                                ECO:0000269|PubMed:9246020}.
FT                                /FTId=VAR_005639.
FT   VARIANT     215    215       R -> H (polymorphism; allele TPMT*8;
FT                                intermediate activity; dbSNP:rs56161402).
FT                                {ECO:0000269|PubMed:16220112,
FT                                ECO:0000269|PubMed:9931346}.
FT                                /FTId=VAR_008715.
FT   VARIANT     227    227       H -> Q (polymorphism; allele TPMT*7;
FT                                reduced activity; dbSNP:rs72552736).
FT                                {ECO:0000269|PubMed:16220112,
FT                                ECO:0000269|PubMed:9711875}.
FT                                /FTId=VAR_005640.
FT   VARIANT     240    240       Y -> C (polymorphism; allele TPMT*3B and
FT                                allele TPMT*3C; reduced activity; protein
FT                                shows enhanced degradation;
FT                                dbSNP:rs1142345).
FT                                {ECO:0000269|PubMed:10208641,
FT                                ECO:0000269|PubMed:10751626,
FT                                ECO:0000269|PubMed:15819814,
FT                                ECO:0000269|PubMed:16220112,
FT                                ECO:0000269|PubMed:16476125,
FT                                ECO:0000269|PubMed:16789994,
FT                                ECO:0000269|PubMed:17243178,
FT                                ECO:0000269|PubMed:8561894,
FT                                ECO:0000269|PubMed:8644731,
FT                                ECO:0000269|PubMed:9246020,
FT                                ECO:0000269|PubMed:9336428,
FT                                ECO:0000269|PubMed:9931345}.
FT                                /FTId=VAR_005641.
FT   MUTAGEN     152    152       R->E: Decreases affinity for 6-
FT                                mercaptopurine. Slightly decreases
FT                                catalytic activity.
FT                                {ECO:0000269|PubMed:18484748}.
FT   TURN         18     21       {ECO:0000244|PDB:2BZG}.
FT   HELIX        26     35       {ECO:0000244|PDB:2BZG}.
FT   HELIX        47     57       {ECO:0000244|PDB:2BZG}.
FT   STRAND       64     67       {ECO:0000244|PDB:2BZG}.
FT   HELIX        75     81       {ECO:0000244|PDB:2BZG}.
FT   STRAND       85     89       {ECO:0000244|PDB:2BZG}.
FT   HELIX        93    102       {ECO:0000244|PDB:2BZG}.
FT   STRAND      107    111       {ECO:0000244|PDB:2BZG}.
FT   STRAND      119    123       {ECO:0000244|PDB:2BZG}.
FT   STRAND      126    133       {ECO:0000244|PDB:2BZG}.
FT   HELIX       135    140       {ECO:0000244|PDB:2BZG}.
FT   STRAND      146    154       {ECO:0000244|PDB:2BZG}.
FT   TURN        155    157       {ECO:0000244|PDB:2BZG}.
FT   HELIX       160    162       {ECO:0000244|PDB:2BZG}.
FT   HELIX       163    172       {ECO:0000244|PDB:2BZG}.
FT   STRAND      174    186       {ECO:0000244|PDB:2BZG}.
FT   TURN        189    191       {ECO:0000244|PDB:2BZG}.
FT   HELIX       201    208       {ECO:0000244|PDB:2BZG}.
FT   TURN        209    211       {ECO:0000244|PDB:2BZG}.
FT   STRAND      212    221       {ECO:0000244|PDB:2BZG}.
FT   HELIX       225    230       {ECO:0000244|PDB:2BZG}.
FT   STRAND      236    244       {ECO:0000244|PDB:2BZG}.
SQ   SEQUENCE   245 AA;  28180 MW;  190E781155B97BB9 CRC64;
     MDGTRTSLDI EEYSDTEVQK NQVLTLEEWQ DKWVNGKTAF HQEQGHQLLK KHLDTFLKGK
     SGLRVFFPLC GKAVEMKWFA DRGHSVVGVE ISELGIQEFF TEQNLSYSEE PITEIPGTKV
     FKSSSGNISL YCCSIFDLPR TNIGKFDMIW DRGALVAINP GDRKCYADTM FSLLGKKFQY
     LLCVLSYDPT KHPGPPFYVP HAEIERLFGK ICNIRCLEKV DAFEERHKSW GIDCLFEKLY
     LLTEK
//
